Irene Pericot-Valverde1, Moonseong Heo2, Jiajing Niu3, Lior Rennert4, Brianna L Norton5, Matthew J Akiyama5, Julia Arnsten5, Alain H Litwin6. 1. Prisma Health Addiction Research Center, Greenville, SC, USA; Clemson University School of Health Research, Clemson University, Clemson, SC, USA. Electronic address: iperico@clemson.edu. 2. Prisma Health Addiction Research Center, Greenville, SC, USA; Clemson University School of Health Research, Clemson University, Clemson, SC, USA; Department of Public Health Sciences, Clemson, SC, USA. 3. School of Mathematical and Statistical Sciences, Clemson University, Clemson, SC, USA. 4. Clemson University School of Health Research, Clemson University, Clemson, SC, USA. 5. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA. 6. Prisma Health Addiction Research Center, Greenville, SC, USA; Clemson University School of Health Research, Clemson University, Clemson, SC, USA; University of South Carolina School of Medicine, Department of Medicine, Greenville, SC, USA. Electronic address: Alain.Litwin@prismahealth.org.
Abstract
BACKGROUND: Interferon-based regimens exacerbated depressive symptoms, which interfered with treating hepatitis C virus (HCV) among people who inject drugs (PWID). Direct-acting antivirals (DAA) are not associated with worsening depressive symptoms; however, the impact of depressive symptoms on adherence remains little known. We examined the association between depressive symptoms and adherence to DAA among HCV-infected PWID. A secondary aim was to identify the optimal cut-off for major depressive disorder for this population. METHODS: Participants were 150 HCV-infected PWID on maintenance treatment enrolled in a randomized clinical trial testing three HCV care models. Severity of depressive symptoms were assessed using the Beck Depression Inventory-II (BDI-II) at baseline and every 4 weeks during treatment. Current major depressive disorder at baseline was diagnosed by the Mini-International Neuropsychiatric Interview. Adherence was measured during treatment (weeks 1-12) using electronic blister packs RESULTS: BDI-II scores ≥ 18 were identified as the optimal threshold for diagnosing major depressive disorder. Participants with BDI scores ≥ 18 at baseline had significantly lower adherence rates at weeks 1-4 of treatment compared to those with BDI scores < 18 (b = -0.23, 95% CI: 0.45-0.01, p = 0.044), but not in any other time intervals (weeks 5-8, b = -0.03, 95% CI: -0.32, 0.26, p = 0.825; weeks 9-12, b = -0.33, 95% CI -0.70, 0.02, p = 0.066). CONCLUSIONS: Elevated depressive symptoms were associated with lower adherence to DAA only during the first 4 weeks of HCV treatment. Neither severe depressive symptoms nor major depressive disorder appears to be a barrier to DAA adherence among PWID.
BACKGROUND: Interferon-based regimens exacerbated depressive symptoms, which interfered with treating hepatitis C virus (HCV) among people who inject drugs (PWID). Direct-acting antivirals (DAA) are not associated with worsening depressive symptoms; however, the impact of depressive symptoms on adherence remains little known. We examined the association between depressive symptoms and adherence to DAA among HCV-infected PWID. A secondary aim was to identify the optimal cut-off for major depressive disorder for this population. METHODS: Participants were 150 HCV-infected PWID on maintenance treatment enrolled in a randomized clinical trial testing three HCV care models. Severity of depressive symptoms were assessed using the Beck Depression Inventory-II (BDI-II) at baseline and every 4 weeks during treatment. Current major depressive disorder at baseline was diagnosed by the Mini-International Neuropsychiatric Interview. Adherence was measured during treatment (weeks 1-12) using electronic blister packs RESULTS: BDI-II scores ≥ 18 were identified as the optimal threshold for diagnosing major depressive disorder. Participants with BDI scores ≥ 18 at baseline had significantly lower adherence rates at weeks 1-4 of treatment compared to those with BDI scores < 18 (b = -0.23, 95% CI: 0.45-0.01, p = 0.044), but not in any other time intervals (weeks 5-8, b = -0.03, 95% CI: -0.32, 0.26, p = 0.825; weeks 9-12, b = -0.33, 95% CI -0.70, 0.02, p = 0.066). CONCLUSIONS: Elevated depressive symptoms were associated with lower adherence to DAA only during the first 4 weeks of HCV treatment. Neither severe depressive symptoms nor major depressive disorder appears to be a barrier to DAA adherence among PWID.
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: K So-Armah; S K Gupta; S Kundu; J C Stewart; J L Goulet; A A Butt; J J Sico; V C Marconi; S Crystal; M C Rodriguez-Barradas; M Budoff; C L Gibert; C-Ch Chang; R Bedimo; M S Freiberg Journal: HIV Med Date: 2019-03-29 Impact factor: 3.180
Authors: John S Cacciola; Arthur I Alterman; A Thomas McLellan; Yi-Ting Lin; Kevin G Lynch Journal: Drug Alcohol Depend Date: 2006-10-11 Impact factor: 4.492
Authors: Matthew J Akiyama; Brianna L Norton; Julia H Arnsten; Linda Agyemang; Moonseong Heo; Alain H Litwin Journal: Ann Intern Med Date: 2019-04-09 Impact factor: 25.391
Authors: Kathleen M Ward; Oluwaseun Falade-Nwulia; Juhi Moon; Catherine G Sutcliffe; Sherilyn Brinkley; Taryn Haselhuhn; Stephanie Katz; Kayla Herne; Lilian Arteaga; Shruti H Mehta; Carl Latkin; Robert K Brooner; Mark S Sulkowski Journal: J Infect Dis Date: 2022-03-02 Impact factor: 7.759
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Matthew J Akiyama; Linda Agyemang; Julia H Arnsten; Moonseong Heo; Brianna L Norton; Bruce R Schackman; Benjamin P Linas; Alain H Litwin Journal: BMC Infect Dis Date: 2018-02-09 Impact factor: 3.667